IL141160A0 - A pharmaceutical composition containing a precursor of uric acid - Google Patents

A pharmaceutical composition containing a precursor of uric acid

Info

Publication number
IL141160A0
IL141160A0 IL14116099A IL14116099A IL141160A0 IL 141160 A0 IL141160 A0 IL 141160A0 IL 14116099 A IL14116099 A IL 14116099A IL 14116099 A IL14116099 A IL 14116099A IL 141160 A0 IL141160 A0 IL 141160A0
Authority
IL
Israel
Prior art keywords
uric acid
precursor
pharmaceutical composition
composition containing
biological modifier
Prior art date
Application number
IL14116099A
Other languages
English (en)
Original Assignee
Hme Entpr Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hme Entpr Llc filed Critical Hme Entpr Llc
Publication of IL141160A0 publication Critical patent/IL141160A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL14116099A 1998-07-31 1999-08-02 A pharmaceutical composition containing a precursor of uric acid IL141160A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12718498A 1998-07-31 1998-07-31
PCT/US1999/017463 WO2000006171A1 (fr) 1998-07-31 1999-08-02 Composition antioxydante et utilisation de celle-ci pour le traitement de pathologies

Publications (1)

Publication Number Publication Date
IL141160A0 true IL141160A0 (en) 2002-02-10

Family

ID=22428746

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14116099A IL141160A0 (en) 1998-07-31 1999-08-02 A pharmaceutical composition containing a precursor of uric acid
IL141160A IL141160A (en) 1998-07-31 2001-01-29 Pharmaceutical composition containing a precursor of uric acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141160A IL141160A (en) 1998-07-31 2001-01-29 Pharmaceutical composition containing a precursor of uric acid

Country Status (9)

Country Link
EP (1) EP1100507B1 (fr)
JP (1) JP2002521451A (fr)
AT (1) ATE352306T1 (fr)
AU (1) AU5250799A (fr)
CA (1) CA2339004C (fr)
DE (1) DE69934987T2 (fr)
ES (1) ES2279627T3 (fr)
IL (2) IL141160A0 (fr)
WO (1) WO2000006171A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696485B1 (en) 1996-04-02 2004-02-24 Mars, Incorporated Procyanidin and cyclo-oxygenase modulator compositions
US6524630B2 (en) 2000-03-22 2003-02-25 Mars, Incorporated Use of cocoa procyanidins combined with acelylsalicyclic acid as an anti-platelet therapy
CA2304869A1 (fr) * 2000-04-07 2001-10-07 Roman Rozencwaig Traitement medical au moyen d'acide urique ou de precurseurs connexes
FR2808192A1 (fr) * 2000-04-28 2001-11-02 Oreal Epichatechine comme inhibiteur de no-synthase et utilisations
US6479547B1 (en) * 2000-11-21 2002-11-12 Arthur Vanmoor Method of treating an infection by enhancing the effectiveness of the human immune system
DE60229215D1 (de) * 2001-02-09 2008-11-20 New Chapter Inc Zusammensetzung und verfahren zur rauchentgiftung
JP2002326922A (ja) * 2001-03-01 2002-11-15 Kose Corp 皮膚外用剤
ITVR20010031A1 (it) * 2001-03-12 2002-09-12 Hisanori Suzuki Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.
WO2009047639A2 (fr) * 2007-07-23 2009-04-16 Keimyung University Industry Academic Cooperation Foundation Thé vert à teneur réduite en épicatéchines
KR101694482B1 (ko) * 2009-09-21 2017-01-10 (주)아모레퍼시픽 녹차의 줄기세포를 함유하는 항산화 및 항노화용 화장료 조성물
WO2013074948A1 (fr) * 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions contenant du resvératrol et des nucléotides
CN105497355A (zh) * 2015-07-23 2016-04-20 四川金堂海纳生物医药技术研究所 一种治疗破伤风的散剂药物及其制备方法
JP7333942B2 (ja) * 2019-06-07 2023-08-28 株式会社スタージェン 神経変性疾患に対するａｔｐ増強療法の効果を予測する方法
CN114377124B (zh) * 2021-07-13 2023-08-25 中国医学科学院输血研究所 次黄嘌呤与注射用人免疫球蛋白的联合用药物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
US5043100A (en) * 1987-07-23 1991-08-27 Rutgers, The State University Of New Jersey Process for manufacture of natural antioxidant products from tea and spent tea
GB8918368D0 (en) * 1989-08-11 1989-09-20 Amco Chemie Gmbh Compositions for treating obstructive airways disease
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5391568A (en) * 1992-07-10 1995-02-21 American Health Foundation Inhibition of lung tumorigenesis by administration of a polyphenol
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
BR9602919A (pt) * 1996-06-27 1999-01-12 Cosmeticos Natural Ind Com Composições cosméticas para o cuidado da pele
AU4699299A (en) * 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity

Also Published As

Publication number Publication date
CA2339004C (fr) 2008-04-01
DE69934987T2 (de) 2007-05-16
AU5250799A (en) 2000-02-21
EP1100507A4 (fr) 2002-07-31
ES2279627T3 (es) 2007-08-16
JP2002521451A (ja) 2002-07-16
WO2000006171A1 (fr) 2000-02-10
EP1100507B1 (fr) 2007-01-24
CA2339004A1 (fr) 2000-02-10
EP1100507A1 (fr) 2001-05-23
ATE352306T1 (de) 2007-02-15
IL141160A (en) 2009-11-18
DE69934987D1 (de) 2007-03-15

Similar Documents

Publication Publication Date Title
Chen et al. The antioxidant procyanidin reduces reactive oxygen species signaling in macrophages and ameliorates experimental colitis in mice
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
Grant et al. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
DE60027719D1 (de) Krebstherapie
EP2305276A3 (fr) Cellules obtenues par liposuccion et utilisation thérapeutique
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
WO2003025149A8 (fr) Populations cellulaires qui co-expriment cd49c et cd90
EP0696456A3 (fr) Combinaison de substances induisant de la nécrose avec des substances qui sont activées par la nécrose pour le traitement sélectif de tumeurs et de maladies inflammatoires
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
BR9808109A (pt) Inibidor terapêutico de células vasculares da musculatura lisa
NO20050793L (no) Anvendelse av urease for inhibering av kreftcellevekst
CO5590913A2 (es) Terapia de combinacion antivirica
YU30002A (sh) Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina
HUP0103112A2 (hu) Glikogén foszforiláz inhibitorok alkalmazása daganatnövekedés gátlására
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
WO2003033678A3 (fr) Methodes d'utilisation d'inhibiteurs de la desacetylase afin de stimuler la differenciation et la regenerescence cellulaires
Pavithran et al. Nail changes due to docetaxel.
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
ES2042529T3 (es) Un procedimiento para preparar una composicion terapeutica combinada de un eliminador de radicales libres o inhibidor metabolico y una proteina biologicamente activa.
AU6207196A (en) Composition and method for treating prostate cancer